{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetics%2FBirth+Defects&page=35",
    "query": {
      "condition": "Genetics/Birth Defects",
      "page": 35
    },
    "page_size": 10
  },
  "pagination": {
    "page": 35,
    "page_size": 10,
    "total_count": 8007,
    "total_pages": 801,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetics%2FBirth+Defects&page=36&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetics%2FBirth+Defects&page=34&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T06:14:28.917Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00267397",
      "title": "Prevalence and Clinical Spectrum of the 22q11 Deletion",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Congenital Disorders"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Children's Healthcare of Atlanta",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "Up to 6 Years"
      },
      "enrollment_count": null,
      "start_date": "1967-01",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2007-05-04",
      "last_synced_at": "2026-10-23T06:14:28.917Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00267397"
    },
    {
      "nct_id": "NCT00590460",
      "title": "Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Fanconi Anemia",
        "Severe Aplastic Anemia"
      ],
      "interventions": [
        {
          "name": "CAMPATH-1H",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Anti-CD45",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Stem cell infusion",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 5,
      "start_date": "2001-07",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2018-05-24",
      "last_synced_at": "2026-10-23T06:14:28.917Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00590460"
    },
    {
      "nct_id": "NCT00709280",
      "title": "Infant Study of Inhaled Saline in Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "7% Hypertonic Saline (HS)",
          "type": "DRUG"
        },
        {
          "name": "0.9% Isotonic Saline (IS)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CF Therapeutics Development Network Coordinating Center",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "59 Months",
        "sex": "ALL",
        "summary": "4 Months to 59 Months"
      },
      "enrollment_count": 321,
      "start_date": "2009-04",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2013-02-12",
      "last_synced_at": "2026-10-23T06:14:28.917Z",
      "location_count": 28,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00709280"
    },
    {
      "nct_id": "NCT04998396",
      "title": "A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Canavan Disease"
      ],
      "interventions": [
        {
          "name": "AAV9 BBP-812",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Aspa Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Months",
        "sex": "ALL",
        "summary": "Up to 30 Months"
      },
      "enrollment_count": 26,
      "start_date": "2021-09-08",
      "completion_date": "2032-10-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-10-23T06:14:28.917Z",
      "location_count": 4,
      "location_summary": "Oakland, California • Chicago, Illinois • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04998396"
    },
    {
      "nct_id": "NCT00027196",
      "title": "Signs and Symptoms Associated With Molecular Defects in Genetically Inherited Heart Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Congenital Heart Defect"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 9999999,
      "start_date": "1998-04",
      "completion_date": "2003-04",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-23T06:14:28.917Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00027196"
    },
    {
      "nct_id": "NCT00571727",
      "title": "Long-Term Treatment With rhIGF-1 in GHIS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Growth Hormone Insensitivity Syndrome"
      ],
      "interventions": [
        {
          "name": "mecasermin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 92,
      "start_date": "1991-05-20",
      "completion_date": "2011-12-15",
      "has_results": true,
      "last_update_posted_date": "2023-07-06",
      "last_synced_at": "2026-10-23T06:14:28.917Z",
      "location_count": 1,
      "location_summary": "Brisbane, California",
      "locations": [
        {
          "city": "Brisbane",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00571727"
    },
    {
      "nct_id": "NCT04392154",
      "title": "Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Lebrikizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1153,
      "start_date": "2020-06-15",
      "completion_date": "2025-04-22",
      "has_results": true,
      "last_update_posted_date": "2025-11-05",
      "last_synced_at": "2026-10-23T06:14:28.917Z",
      "location_count": 160,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 124 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04392154"
    },
    {
      "nct_id": "NCT00102791",
      "title": "A Stratified Sickle Event Randomized Trial (ASSERT)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "ICA-17043",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icagen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "16 Years to 65 Years"
      },
      "enrollment_count": 297,
      "start_date": "2005-02",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2008-03-27",
      "last_synced_at": "2026-10-23T06:14:28.917Z",
      "location_count": 42,
      "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Davis, California + 39 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00102791"
    },
    {
      "nct_id": "NCT06228924",
      "title": "Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Arrhythmogenic Right Ventricular Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "TN-401",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Tenaya Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 15,
      "start_date": "2024-03-26",
      "completion_date": "2029-10-01",
      "has_results": false,
      "last_update_posted_date": "2025-02-06",
      "last_synced_at": "2026-10-23T06:14:28.917Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06228924"
    },
    {
      "nct_id": "NCT01505062",
      "title": "Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Usher Syndrome",
        "Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "SAR421869",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2012-03-26",
      "completion_date": "2019-08-16",
      "has_results": true,
      "last_update_posted_date": "2022-04-28",
      "last_synced_at": "2026-10-23T06:14:28.917Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01505062"
    }
  ]
}